132 related articles for article (PubMed ID: 33729773)
1. Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion.
Cockerill GS; Angell RM; Bedernjak A; Chuckowree I; Fraser I; Gascon-Simorte J; Gilman MSA; Good JAD; Harland R; Johnson SM; Ludes-Meyers JH; Littler E; Lumley J; Lunn G; Mathews N; McLellan JS; Paradowski M; Peeples ME; Scott C; Tait D; Taylor G; Thom M; Thomas E; Villalonga Barber C; Ward SE; Watterson D; Williams G; Young P; Powell K
J Med Chem; 2021 Apr; 64(7):3658-3676. PubMed ID: 33729773
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
DeVincenzo J; Tait D; Efthimiou J; Mori J; Kim YI; Thomas E; Wilson L; Harland R; Mathews N; Cockerill S; Powell K; Littler E
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712214
[TBL] [Abstract][Full Text] [Related]
3. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study.
Mackman RL; Sangi M; Sperandio D; Parrish JP; Eisenberg E; Perron M; Hui H; Zhang L; Siegel D; Yang H; Saunders O; Boojamra C; Lee G; Samuel D; Babaoglu K; Carey A; Gilbert BE; Piedra PA; Strickley R; Iwata Q; Hayes J; Stray K; Kinkade A; Theodore D; Jordan R; Desai M; Cihlar T
J Med Chem; 2015 Feb; 58(4):1630-43. PubMed ID: 25574686
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus fusion inhibitors. Part 4: optimization for oral bioavailability.
Yu KL; Sin N; Civiello RL; Wang XA; Combrink KD; Gulgeze HB; Venables BL; Wright JJ; Dalterio RA; Zadjura L; Marino A; Dando S; D'Arienzo C; Kadow KF; Cianci CW; Li Z; Clarke J; Genovesi EV; Medina I; Lamb L; Colonno RJ; Yang Z; Krystal M; Meanwell NA
Bioorg Med Chem Lett; 2007 Feb; 17(4):895-901. PubMed ID: 17169560
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor.
Zheng X; Gao L; Wang L; Liang C; Wang B; Liu Y; Feng S; Zhang B; Zhou M; Yu X; Xiang K; Chen L; Guo T; Shen HC; Zou G; Wu JZ; Yun H
J Med Chem; 2019 Jul; 62(13):6003-6014. PubMed ID: 31194544
[TBL] [Abstract][Full Text] [Related]
6. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
[TBL] [Abstract][Full Text] [Related]
7. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121).
Bonfanti JF; Meyer C; Doublet F; Fortin J; Muller P; Queguiner L; Gevers T; Janssens P; Szel H; Willebrords R; Timmerman P; Wuyts K; van Remoortere P; Janssens F; Wigerinck P; Andries K
J Med Chem; 2008 Feb; 51(4):875-96. PubMed ID: 18254606
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Benzoazepinequinoline (BAQ) Derivatives as Novel, Potent, Orally Bioavailable Respiratory Syncytial Virus Fusion Inhibitors.
Zheng X; Liang C; Wang L; Wang B; Liu Y; Feng S; Wu JZ; Gao L; Feng L; Chen L; Guo T; Shen HC; Yun H
J Med Chem; 2018 Nov; 61(22):10228-10241. PubMed ID: 30339388
[TBL] [Abstract][Full Text] [Related]
9. A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.
Gaillard V; Galloux M; Garcin D; Eléouët JF; Le Goffic R; Larcher T; Rameix-Welti MA; Boukadiri A; Héritier J; Segura JM; Baechler E; Arrell M; Mottet-Osman G; Nyanguile O
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137809
[TBL] [Abstract][Full Text] [Related]
10. Labyrinthopeptins as virolytic inhibitors of respiratory syncytial virus cell entry.
Blockus S; Sake SM; Wetzke M; Grethe C; Graalmann T; Pils M; Le Goffic R; Galloux M; Prochnow H; Rox K; Hüttel S; Rupcic Z; Wiegmann B; Dijkman R; Rameix-Welti MA; Eléouët JF; Duprex WP; Thiel V; Hansen G; Brönstrup M; Haid S; Pietschmann T
Antiviral Res; 2020 May; 177():104774. PubMed ID: 32197980
[TBL] [Abstract][Full Text] [Related]
11. Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus.
Pribut N; Kaiser TM; Wilson RJ; Jecs E; Dentmon ZW; Pelly SC; Sharma S; Bartsch PW; Burger PB; Hwang SS; Le T; Sourimant J; Yoon JJ; Plemper RK; Liotta DC
ACS Infect Dis; 2020 May; 6(5):922-929. PubMed ID: 32275393
[TBL] [Abstract][Full Text] [Related]
12. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.
Cianci C; Genovesi EV; Lamb L; Medina I; Yang Z; Zadjura L; Yang H; D'Arienzo C; Sin N; Yu KL; Combrink K; Li Z; Colonno R; Meanwell N; Clark J; Krystal M
Antimicrob Agents Chemother; 2004 Jul; 48(7):2448-54. PubMed ID: 15215093
[TBL] [Abstract][Full Text] [Related]
13. Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model.
Ispas G; Koul A; Verbeeck J; Sheehan J; Sanders-Beer B; Roymans D; Andries K; Rouan MC; De Jonghe S; Bonfanti JF; Vanstockem M; Simmen K; Verloes R
PLoS One; 2015; 10(5):e0126959. PubMed ID: 26010881
[TBL] [Abstract][Full Text] [Related]
14. Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors.
Feng S; Li C; Chen D; Zheng X; Yun H; Gao L; Shen HC
Eur J Med Chem; 2017 Sep; 138():1147-1157. PubMed ID: 28772235
[TBL] [Abstract][Full Text] [Related]
15. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms.
Douglas JL; Panis ML; Ho E; Lin KY; Krawczyk SH; Grant DM; Cai R; Swaminathan S; Chen X; Cihlar T
Antimicrob Agents Chemother; 2005 Jun; 49(6):2460-6. PubMed ID: 15917547
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.
Coates M; Brookes D; Kim YI; Allen H; Fordyce EAF; Meals EA; Colley T; Ciana CL; Parra GF; Sherbukhin V; Stockwell JA; Thomas JC; Hunt SF; Anderson-Dring L; Onions ST; Cass L; Murray PJ; Ito K; Strong P; DeVincenzo JP; Rapeport G
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652242
[TBL] [Abstract][Full Text] [Related]
17. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
[TBL] [Abstract][Full Text] [Related]
18. Orally active fusion inhibitor of respiratory syncytial virus.
Cianci C; Yu KL; Combrink K; Sin N; Pearce B; Wang A; Civiello R; Voss S; Luo G; Kadow K; Genovesi EV; Venables B; Gulgeze H; Trehan A; James J; Lamb L; Medina I; Roach J; Yang Z; Zadjura L; Colonno R; Clark J; Meanwell N; Krystal M
Antimicrob Agents Chemother; 2004 Feb; 48(2):413-22. PubMed ID: 14742189
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies for an old virus: treatment of RSV infections in the 21st Century.
Lüsebrink J; Schildgen V; Schildgen O
Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1125-9. PubMed ID: 19883332
[TBL] [Abstract][Full Text] [Related]
20. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate, part 1: improving the pharmacokinetic profile using the structure-property relationship.
Bonfanti JF; Doublet F; Fortin J; Lacrampe J; Guillemont J; Muller P; Queguiner L; Arnoult E; Gevers T; Janssens P; Szel H; Willebrords R; Timmerman P; Wuyts K; Janssens F; Sommen C; Wigerinck P; Andries K
J Med Chem; 2007 Sep; 50(19):4572-84. PubMed ID: 17722899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
